ModerateDirect oral anticoagulants (factor Xa inhibitors)×Non-dihydropyridine calcium channel blocker
Updated · Methodology
Mechanism
Edoxaban is a substrate of P-glycoprotein (P-gp), an efflux transporter (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Verapamil inhibits P-gp and the enzyme CYP3A4 (verapamil SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Verapamil 240 mg once daily for 11 days raised the edoxaban area under the concentration–time curve (AUC) and peak concentration by about 53% (edoxaban SmPC, EMA). According to the verapamil SmPC, direct oral anticoagulants are absorbed to a greater extent because they are P-gp substrates. Some data suggest that the risk of bleeding may rise, especially in patients with risk factors (verapamil SmPC, AEMPS). Edoxaban in turn lowered verapamil peak concentration by 14% and AUC by 16% (edoxaban SmPC, EMA).
Symptoms
Edoxaban increases the risk of bleeding and can cause severe, potentially fatal bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds (7.7%), blood in the urine (6.9%) and anaemia (5.3%). Common adverse reactions also include gastrointestinal bleeding, bleeding in the mouth and throat, vaginal bleeding, and bleeding into the skin and soft tissues (edoxaban SmPC, EMA). Bleeding complications can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock of unknown cause (edoxaban SmPC, EMA).
Management
The combination is not contraindicated. Under the European edoxaban summary of product characteristics (SmPC), verapamil does not call for a lower edoxaban dose (edoxaban SmPC, European Medicines Agency, EMA). The verapamil SmPC says to reduce the dose of a direct oral anticoagulant, if needed, as that anticoagulant's own SmPC recommends (verapamil SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In atrial fibrillation and in the treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), the edoxaban dose is 60 mg once daily. The 30 mg once-daily dose is only for other reasons: creatinine clearance of 15–50 mL/min, body weight of 60 kg or less, or ciclosporin, dronedarone, erythromycin or ketoconazole (edoxaban SmPC, EMA). The US edoxaban label follows a different scheme. In DVT and PE treatment, patients taking certain P-glycoprotein (P-gp) inhibitors get 30 mg once daily, and in the trial these inhibitors included verapamil. In atrial fibrillation, the dose is not changed for these inhibitors (edoxaban label, US Food and Drug Administration, FDA). In the European Heart Rhythm Association practical guide, the pair is marked yellow (EHRA 2021). Edoxaban exposure rises by 53%, and the label requires no dose reduction. EHRA states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include age 75 years or older, chronic kidney disease, antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, and previous bleeding or a predisposition to it (EHRA 2021). Watch for signs of bleeding and anaemia during treatment. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). Check creatinine clearance at the start of treatment in all patients and later when clinically indicated (edoxaban SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- AEMPS: Ficha técnica: Verapamilo, Manidon Retard 120 mg (nº registro 53434), sección 4.5 (2024)– AEMPS, CIMA, nº registro 53434, revisión 06/2024, sección 4.5
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2